Bellicum Pharmaceuticals Inc. buy klostergang
Start price
22.05.19
/
50%
€24.72
Target price
26.11.19
€45.10
Performance (%)
-68.44%
End price
26.11.19
€7.80
Summary
This prediction ended on 26.11.19 with a price of €7.80. Massive losses of -68.44% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bellicum Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 0,61 % | 0,34 % | 12,06 % | 58,10 % |
| iShares Nasdaq 100 | 0,64 % | -3,17 % | 1,74 % | 84,36 % |
| iShares Nikkei 225® | -0,13 % | 8,92 % | 27,39 % | 64,84 % |
| iShares S&P 500 | 0,54 % | -0,70 % | 1,91 % | 58,67 % |
Comments by klostergang for this prediction
In the thread Bellicum Pharmaceuticals Inc. diskutieren
klostergang stimmt dem Sentiment von 'Buy' zu
The June 26, 2017 updated results Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) presented for BPX-501, validated its controllable cell therapy platform. This, according to the firm, is supportive of a potential new standard of care in haploidentical stem cell transplant.
BPX-501 is an allogenic T cell add-back product used after a T-cell depleted haploidentical allogenic hematopoietic stem cell transplant for both benign and malignant hematologic diseases.
As such, Wells Fargo has an Outperform rating on the shares of Bellicum, with a $31 price target.
Kursziel geändert auf 2,0
Stopped prediction by klostergang for Bellicum Pharmaceuticals Inc.
Bellicum Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€3.96
15.03.20
15.03.20
€12.00
04.11.21
04.11.21
-36.36%
17.06.21
17.06.21
Bellicum Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€9.05
13.02.20
13.02.20
-
25.02.20
25.02.20
-6.08%
25.02.20
25.02.20
Bellicum Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€105.26
02.07.17
02.07.17
€180.40
20.05.19
20.05.19
-74.89%
20.05.19
20.05.19